Your browser is no longer supported. Please, upgrade your browser.
Settings
MRNS Marinus Pharmaceuticals, Inc. daily Stock Chart
MRNS [NASD]
Marinus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.98 Insider Own0.10% Shs Outstand83.83M Perf Week35.71%
Market Cap254.84M Forward P/E- EPS next Y-0.67 Insider Trans116.45% Shs Float83.83M Perf Month31.60%
Income-48.80M PEG- EPS next Q-0.21 Inst Own48.00% Short Float6.02% Perf Quarter178.90%
Sales- P/S- EPS this Y-11.90% Inst Trans18.47% Short Ratio2.86 Perf Half Y171.43%
Book/sh0.65 P/B4.68 EPS next Y28.70% ROA-78.90% Target Price5.38 Perf Year-17.84%
Cash/sh0.48 P/C6.39 EPS next 5Y- ROE-94.50% 52W Range0.77 - 5.40 Perf YTD40.74%
Dividend- P/FCF- EPS past 5Y-3.90% ROI- 52W High-43.70% Beta3.29
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low294.81% ATR0.21
Employees41 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)79.13 Volatility13.34% 8.40%
OptionableYes Debt/Eq0.00 EPS Q/Q4.40% Profit Margin- Rel Volume1.58 Prev Close2.61
ShortableYes LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume1.76M Price3.04
Recom1.40 SMA2037.22% SMA5046.79% SMA20032.39% Volume2,811,982 Change16.48%
Dec-20-19Initiated Oppenheimer Outperform
Mar-05-19Resumed Jefferies Buy $3.50 → $10
Feb-27-19Downgrade Mizuho Buy → Neutral $13 → $5
Feb-06-19Initiated Leerink Partners Outperform $10
Jul-02-18Initiated Cantor Fitzgerald Overweight $19
Mar-20-18Initiated Mizuho Buy $13
Feb-15-18Initiated H.C. Wainwright Buy $33
Dec-14-17Initiated Laidlaw Buy $18
Aug-10-16Reiterated Jefferies Buy $2.50 → $3
Jun-14-16Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-08-16Reiterated Stifel Buy $23 → $16
Dec-17-15Initiated RBC Capital Mkts Outperform $14
Nov-17-15Initiated Jefferies Buy $14
Oct-30-15Reiterated Oppenheimer Outperform $21 → $17
Aug-05-15Reiterated Oppenheimer Outperform $12 → $21
Feb-14-20 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Feb-03-20 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting GlobeNewswire
Jan-20-20 04:37AM  3 Top-Notch Strong Buy Stocks Under $3 TipRanks
Jan-13-20 07:30AM  Marinus Provides Business Outlook for 2020 GlobeNewswire
Jan-07-20 07:30AM  Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference GlobeNewswire
Dec-26-19 09:00AM  Marinus Pharmaceuticals (MRNS) Catches Eye: Stock Jumps 7.7% Zacks -5.98%
Dec-24-19 11:29AM  Were Hedge Funds Right Selling Marinus Pharmaceuticals Inc (MRNS)? Insider Monkey +7.73%
Dec-23-19 08:30AM  Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options Zacks +7.37%
Dec-13-19 04:44PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -5.26%
04:01PM  Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-12-19 07:30AM  Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors GlobeNewswire
Dec-11-19 12:09PM  Main Line biopharma firm expects $65M from stock sale; shares soar American City Business Journals +37.98%
10:31AM  Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire
09:00AM  Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire
07:21AM  The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Benzinga
Dec-10-19 04:25PM  Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement GlobeNewswire
Dec-09-19 06:30AM  Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex GlobeNewswire
Dec-07-19 12:01AM  Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting GlobeNewswire
Nov-27-19 07:30AM  Marinus Pharmaceuticals Announces Presentations on Ganaxolone at AES Annual Meeting GlobeNewswire +7.14%
Nov-08-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-06-19 07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results GlobeNewswire -5.74%
Oct-29-19 07:30AM  Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer GlobeNewswire
Oct-17-19 07:30AM  Marinus Phase 2 Clinical Data on Ganaxolone in RSE Presented at Neurocritical Care Society Meeting GlobeNewswire
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Sep-27-19 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -10.06%
03:08PM  A Look At Benzinga Pro's Most-Searched Tickers For September 27, 2019 Benzinga
Sep-26-19 04:32PM  A Look At Benzinga Pro's Most-Searched Tickers For September 26, 2019 Benzinga +23.36%
11:16AM  Marinus Shares Rip Higher On Positive Ganaxolone Midstage Data In Epileptic Seizures Benzinga
07:30AM  Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial GlobeNewswire
Sep-25-19 11:36AM  Is the Options Market Predicting a Spike in Marinus (MRNS) Stock? Zacks +7.87%
Sep-20-19 09:36AM  Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth? Simply Wall St.
Aug-23-19 04:06PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
09:19AM  Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock? Zacks
Aug-09-19 12:00PM  Main Line pharmaceutical firm finds new CEO in-house American City Business Journals
Aug-08-19 07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results GlobeNewswire +8.41%
Jul-23-19 01:53PM  Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today Motley Fool -70.10%
11:30AM  Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days Benzinga
07:30AM  Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression GlobeNewswire
Jun-29-19 07:18PM  Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy? Insider Monkey
Jun-27-19 12:46PM  5 stocks trading at under $10 worth discovering MarketWatch +7.99%
Jun-20-19 11:22AM  Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years Simply Wall St.
Jun-19-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Jun-03-19 07:30AM  Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences GlobeNewswire +5.57%
May-27-19 09:22AM  Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study Zacks
May-01-19 07:53AM  Marinus Pharmaceuticals: 1Q Earnings Snapshot Associated Press -15.99%
07:30AM  Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-26-19 01:19PM  How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own? Simply Wall St. +6.78%
Mar-19-19 08:46AM  Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options Zacks
Mar-11-19 09:57AM  Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings Zacks
09:55AM  Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing? Zacks
07:30AM  Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results GlobeNewswire
Mar-06-19 07:30AM  Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy GlobeNewswire
Mar-05-19 02:51PM  Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why Benzinga +6.74%
07:30AM  Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference GlobeNewswire
Feb-26-19 03:31PM  Main Line biopharm CEO stepping down American City Business Journals
09:00AM  Marinus Announces Leadership Transition GlobeNewswire
Feb-20-19 07:30AM  Marinus Pharmaceuticals to Present at the Leerink Healthcare Conference GlobeNewswire
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace -7.92%
Feb-05-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jan-30-19 07:35AM  New Research Coverage Highlights Heron Therapeutics, IDACORP, Star Bulk Carriers, AngioDynamics, Marinus Pharmaceuticals, and Advaxis Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-25-19 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.13%
Dec-22-18 01:54AM  Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS) Insider Monkey
Dec-13-18 12:25PM  Marinus Pharmaceuticals plans $45M stock sale American City Business Journals -11.88%
Dec-12-18 08:26PM  Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock GlobeNewswire -17.45%
04:12PM  Here's Why Marinus Pharmaceuticals Is Sinking Today Motley Fool
08:07AM  The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel Benzinga
Dec-11-18 04:01PM  Marinus Pharmaceuticals Announces Public Offering of Common Stock GlobeNewswire
Dec-10-18 12:50PM  Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials Benzinga
07:30AM  Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression GlobeNewswire
Dec-04-18 07:30AM  Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients GlobeNewswire -8.13%
Nov-19-18 07:30AM  Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES GlobeNewswire
Nov-16-18 11:56AM  Granite Point Capitals Returns, AUM, and Holdings Insider Monkey
Nov-06-18 08:37AM  Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock? Zacks
07:30AM  Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-29-18 07:36AM  Marinus Pharmaceuticals: 3Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results GlobeNewswire
Oct-10-18 07:30AM  Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance GlobeNewswire -13.32%
Oct-09-18 04:48PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Oct-05-18 04:00PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -10.82%
Sep-28-18 02:28PM  What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)? Simply Wall St.
Sep-25-18 07:30AM  Marinus Completes Enrollment in its Magnolia Postpartum Depression Study GlobeNewswire
Sep-24-18 10:30AM  Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market ACCESSWIRE
Sep-20-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-30-18 04:15PM  Marinus Pharmaceuticals to Present at the Baird Healthcare Conference GlobeNewswire
Aug-28-18 07:30AM  Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Aug-09-18 10:15AM  7 Biotech Stocks With Big Upcoming Catalysts Kiplinger
Aug-07-18 07:30AM  Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference GlobeNewswire
Aug-02-18 02:48PM  Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today Motley Fool -13.02%
09:14AM  Marinus Pharmaceuticals: 2Q Earnings Snapshot Associated Press
07:30AM  Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-21-18 08:44AM  Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga
Jul-16-18 07:05AM  Free Technical Research on Marinus Pharma and Three More Biotech Equities ACCESSWIRE
Jul-12-18 12:54PM  Harry Boxers four health-care stocks to watch MarketWatch
Jul-11-18 10:52AM  Pfizer Doesn't Look Fundamentally or Technically Strong TheStreet.com
Jun-27-18 08:25AM  Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-21-18 07:30AM  Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index GlobeNewswire
Jun-19-18 07:30AM  Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder GlobeNewswire
Jun-15-18 04:05PM  Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edward FCFOJan 30Sale2.052,3804,87917,717Feb 03 06:29 PM
Braunstein ScottChief Executive OfficerDec 13Buy1.25100,000125,000100,000Dec 13 04:08 PM
Smith Edward FCFOMay 16Sale5.0324,211121,78120,097May 20 04:20 PM
Cashman Christopher MichaelCEOMar 18Option Exercise1.0431,66232,928271,423Mar 20 05:57 PM